Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.20 is 83% above its 5-year average of -1.16, near the high end of its 5-year range (-2.93–0.14).
303.77% below its 12-month average of 0.10.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.12.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T13:26:45.298Z. Historical observations retain their original dates. Historical series through 2026-03-13.
EARNINGS PER SHARE (EPS)
-0.20
EARNINGS PER SHARE (EPS) AVG TTM
0.10
EARNINGS PER SHARE (EPS) AVG 3Y
-0.30
EARNINGS PER SHARE (EPS) AVG 5Y
-1.16
EARNINGS PER SHARE (EPS) AVG 10Y
-8.48
EARNINGS PER SHARE (EPS) AVG 15Y
-11.04
EARNINGS PER SHARE (EPS) AVG 20Y
-7.54
CURRENT VS TTM AVG
-303.77%
CURRENT VS 3Y AVG
+32.42%
CURRENT VS 5Y AVG
+82.82%
CURRENT VS 10Y AVG
+97.64%
CURRENT VS 15Y AVG
+98.19%
CURRENT VS 20Y AVG
+97.35%
Gyre Therapeutics, Inc.
Market Cap
$819.44M
Earnings Per Share (EPS)
-0.20
TTM Avg
0.10
3Y Avg
-0.30
5Y Avg
-1.16
Market Cap
$837.43M
Earnings Per Share (EPS)
-0.23
TTM Avg
-0.22
3Y Avg
-0.29
5Y Avg
-0.62
Market Cap
$844.28M
Earnings Per Share (EPS)
-3.80
TTM Avg
-6.69
3Y Avg
-9.43
5Y Avg
-9.43
Market Cap
$786.48M
Earnings Per Share (EPS)
-0.62
TTM Avg
-0.28
3Y Avg
-0.16
5Y Avg
-0.10
Market Cap
$852.55M
Earnings Per Share (EPS)
-1.68
TTM Avg
-1.54
3Y Avg
-1.41
5Y Avg
-1.41
Market Cap
$856.30M
Earnings Per Share (EPS)
-2.75
TTM Avg
-44.66
3Y Avg
-65.84
5Y Avg
-51.72
Market Cap
$780.95M
Earnings Per Share (EPS)
-1.68
TTM Avg
0.05
3Y Avg
-1.18
5Y Avg
-0.72
Market Cap
$776.24M
Earnings Per Share (EPS)
-0.10
TTM Avg
-0.20
3Y Avg
-0.27
5Y Avg
-0.29
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gyre Therapeutics, Inc. (GYRE) | $819.44M | -0.20 | 0.10 | -0.30 | -1.16 |
| InMode Ltd. (INMD)vs › | $812.20M | 1.23 | 1.87 | 2.02 | 1.86 |
| Ardelyx, Inc. (ARDX)vs › | $837.43M | -0.23 | -0.22 | -0.29 | -0.62 |
| Alumis Inc. (ALMS)vs › | $844.28M | -3.80 | -6.69 | -9.43 | -9.43 |
| Cytek Biosciences, Inc. (CTKB)vs › | $786.48M | -0.62 | -0.28 | -0.16 | -0.10 |
| Beta Bionics, Inc. (BBNX)vs › | $852.55M | -1.68 | -1.54 | -1.41 | -1.41 |
| Jade Biosciences, Inc. (JBIO)vs › | $856.30M | -2.75 | -44.66 | -65.84 | -51.72 |
| AdaptHealth Corp. (AHCO)vs › | $780.95M | -1.68 | 0.05 | -1.18 | -0.72 |
| Geron Corporation (GERN)vs › | $776.24M | -0.10 | -0.20 | -0.27 | -0.29 |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | -1.18 | -1.05 | -1.11 | -0.92 |
Trailing EPS (TTM)
$-0.20
Forward EPS (Est.)
$-0.40
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 0.06 |
| 2024-12-31 | 0.14 |
| 2023-12-31 | -1.41 |
| 2022-12-31 | 0.03 |
| 2021-12-31 | -2.87 |
| 2020-12-31 | -2.93 |
| 2019-12-31 | -4.41 |
| 2018-12-31 | -2.68 |
| 2017-12-31 | -7.45 |
| 2016-12-31 | -21.76 |
| 2015-12-31 | -49.99 |
| 2013-12-31 | -145.78 |
| 2012-12-31 | -21.95 |
| 2011-12-31 | -28.31 |
| 2010-12-31 | 39.90 |
| 2009-12-31 | -161.39 |
| 2008-12-31 | -109.24 |
| 2007-12-31 | -149.47 |
| 2006-12-31 | -9.45 |
| 2004-12-31 | -20635.57 |
| 2003-12-31 | -8270.79 |
| 2002-12-31 | -8095.27 |
| 2001-12-31 | -2805.22 |
